Kazuto Yamazaki

Kazuto Yamazaki

Auto-generated profile, based on publicly available information

Kazuto Yamazaki

Department of Pathology, Teikyo University Chiba Medical Center

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2005 in Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
KYK Yamazaki
K Yamazaki
MHM Hasegawa
M Hasegawa
IOI Ohoka
I Ohoka
KHK Hanami
K Hanami
AAA Asoh
A Asoh
YIY Ishida
Y Ishida
Background: The retinoblastoma (Rb) pathway, which governs cell cycle progression, is frequently genetically altered in cancer, causing deregulated expression of the E2F-1 transcription factor, which promotes DNA synthesis and cell cycle progression. Recent studies show that E2F-1 also participates in apoptosis induction in a p53 dependent or independent manner. Despite its crucial role and paradoxical effects on cell turnover, the function of E2F-1 in human cancer is unclear. Aims: To evaluate E2F-1 expression using immunohistochemistry in 43 surgically resected oesophageal squamous cell carcinoma (OSCC) specimens. Methods: This study analysed the association of E2F-1 with tumour cell proliferation and apoptosis and the upstream regulators modulating these processes, and its impact on patient outcome. Tumour cell proliferation and apoptosis were assessed as percentage of MIB-1 positive or apoptotic cells (MIB-1 labelling index (MI) and apoptotic index (AI)), respectively. Results: Entire specimens showed abnormal expression of one or more upstream regulators of pRb/E2F-1. Although E2F-1 positivity was not associated with the expression of upstream regulators, it showed a linear and positive correlation with MI but not AI. Patients with high MI, low AI, or high E2F-1 positivity had significantly shorter recurrence free survival. By multivariate analysis, high MI and low AI were independently associated with recurrence free survival, but E2F-1 was not. Conclusions: Increased cell proliferation and decreased apoptosis are associated with adverse prognosis in patients with OSCC. Although E2F-1 remains a controversial prognostic factor, its expression was closely associated with tumour cell proliferation and might influence clinical outcome, mainly via cell cycle progression.

26 August 2021 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
SKSeiji Kobayashi
Seiji Kobayashi
KFKazunori Fugo
Kazunori Fugo
KYKazuto Yamazaki
Kazuto Yamazaki
HTHiroyuki Terawaki
Hiroyuki Terawaki
We report on the onset of minimal change disease (MCD) presenting with anasarca after a second dose of the messenger RNA (mRNA)-based Pfizer-BioNTech vaccine against coronavirus disease 2019 (COVID-19). A 75-year-old previously healthy male was admitted with rapidly progressive anasarca and proteinuria of 7.7 g/day following the second dose. A kidney biopsy revealed MCD with nephrotic syndrome. He was treated with intravenous methylprednisolone followed by prednisolone, leading to complete remission after 35 days in the hospital. Since definite causality between the vaccine and MCD remains unclear, awareness of this potential adverse effect of mRNA vaccines is important to determine its true incidence and frequency.

6 April 2012 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
SYSo Yamada
So Yamada
SYShoko Merrit Yamada
Shoko Merrit Yamada
HNHiroshi Nakaguchi
Hiroshi Nakaguchi
MMMineko Murakami
Mineko Murakami
KHKatsumi Hoya
Katsumi Hoya
YIYasuo Ishida
Yasuo Ishida
Tumefactive multiple sclerosis is a demyelinating disease that demonstrates tumor-like features on magnetic resonance imaging. Although diagnostic challenges without biopsy have been tried by employing radiological studies and cerebrospinal fluid examinations, histological investigation is still necessary for certain diagnosis in some complicated cases.

1 January 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
YGYoshiaki Goto
Yoshiaki Goto
SYSo Yamada
So Yamada
SYShoko M Yamada
Shoko M Yamada
HNHiroshi Nakaguchi
Hiroshi Nakaguchi
KHKatsumi Hoya
Katsumi Hoya
AMAkira Matsuno
Akira Matsuno
Combined chemotherapy and prophylactic cranial irradiation has improved the prognosis of children with acute leukemia. However cranial irradiation carries a latent risk of the induction of secondary intracranial tumors. We encountered a patient who developed multiple intracranial radiation-induced meningiomas (RIMs) 25 years after prophylactic cranial irradiation for the treatment of acute leukemia in childhood. The patient had 3 intracranial lesions, 1 of which showed rapid growth within 6 months; another of the tumors also enlarged within a short period. All of the tumors were surgically treated, and immunohistochemistry indicated a high MIB-1 labeling index in each of the multiple lesions. In the literature, the MIB-1 labeling indices of 27 tumors from 21 patients were examined. Among them, 12 recurrent tumors showed higher MIB-1 labeling indices compared to the MIB-1 labeling indices of the non-recurrent tumors. Overall, 11 of the patients with RIM had multiple lesions and 8 cases developed recurrence (72.7%). RIM cases with multiple lesions had higher MIB-1 labeling indices compared to the MIB-1 labeling indices of cases with single lesions. Collectively, these data showed that the MIB-1 labeling index is as important for predicting RIM recurrences, as it is for predicting sporadic meningioma (SM) recurrences. RIMs should be treated more aggressively than SMs because of their greater malignant potential.

25 November 2020 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
RKRyuji Kojima
Ryuji Kojima
JMJunichi Morimoto
Junichi Morimoto
YIYasuo Ishida
Yasuo Ishida
ISIsamu Sugano
Isamu Sugano
KYKazuto Yamazaki
Kazuto Yamazaki

20 December 2013 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
YTYasuhiro Toyonaga
Yasuhiro Toyonaga
KYKazuto Yamazaki
Kazuto Yamazaki
MYMasatoshi Yamada
Masatoshi Yamada
TKTakayoshi Koyasu
Takayoshi Koyasu
YKYoshinori Koyama
Yoshinori Koyama
YIYasuo Ishida
Yasuo Ishida